Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pseudoephedrine, PPA, nicotine therapy behind-the-counter status urged by PPSI.

This article was originally published in The Tan Sheet

Executive Summary

PSEUDOEPHEDRINE, PPA, SMOKING CESSATION AID BEHIND-THE-COUNTER PLACEMENT URGED in a recent mailing to 40,000 pharmacies by California-based Pharmacists Planning Service, Inc. (PPSI). The non-profit pharmacy education organization advised pharmacists to remove from self-service areas all pseudoephedrine and ephedrine-containing products, phenylpropanolamine (PPA) diet pills and nicotine patches and gums. These products, PPSI asserted, should "only be available with the assistance of a pharmacist or a health professional."

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel